Amylyx Pharmaceuticals, Inc. AMLX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $226.65M+193% | $77.39M-54.5% | $170.2M+172% | $62.53M+24.6% | ||
| $90.33M-8.9% | $99.11M-50.7% | $201.16M-29.3% | $284.42M+519% | ||
| $323.67M+70.9% | $189.43M-59.2% | $464.67M+21.6% | $382.13M+264% | ||
| $310K-67.7% | $961K-64.2% | $2.69M+2.9% | $2.61M+451% | ||
| $332.65M+71.8% | $193.63M-62.6% | $517.45M+32.2% | $391.45M+271% | ||
| $16.96M-45.0% | $30.83M-51.7% | $63.9M+103% | $31.47M+761% | ||
| $22.69M-20.1% | $28.41M-65.4% | $82.04M+76.0% | $46.61M+168% | ||
| $27.39M-5.1% | $28.87M-65.6% | $84.02M+65.2% | $50.85M+192% | ||
| $11K+57.1% | $7K0.0% | $7K0.0% | $7K+600% | ||
| -$751.43M-23.9% | -$606.69M-98.9% | -$304.95M+13.9% | -$354.22M-127% | ||
| $305.26M+85.3% | $164.77M-62.0% | $433.43M+27.3% | $340.61M+325% | ||
| $332.65M+71.8% | $193.63M-62.6% | $517.45M+32.2% | $391.45M+271% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Amylyx Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 17.85 — current assets exceed current liabilities.
- Where does Amylyx Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.